“Lebrikizumab Delivers Clinically Meaningful and Continuous Improvement in Itch-Free Days in Atopic Dermatitis Through One Year”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 6, Nov. 2023, p. s273, https://doi.org/10.25251/skin.7.supp.273.